Literature DB >> 11044557

Effect of an intravitreal cyclosporine implant on experimental uveitis in horses.

B C Gilger1, E Malok, T Stewart, D Horohov, P Ashton, T Smith, G J Jaffe, J B Allen.   

Abstract

The purpose of this study was to determine the effects of an intravitreal device releasing cyclosporine A (CsA) on recurrent inflammatory episodes in experimental uveitis. Nine normal horses were immunized peripherally with H37RA-mTB antigen twice, and then received 25 microg of H37RA-mTB antigen intravitreally in the right eye and an equal volume of balanced salt solution intravitreally in the left eye. Two weeks later, the animals randomly received either a CsA or a polymer implant (without CsA) in both eyes 1 week following implantation of the devices, 25 microg of H37RA-mTB antigen was reinjected into the right eye of each animal. Clinical signs of ophthalmic inflammation were graded following injections and implantation. The animals from each group were euthanized at 3, 14, and 28 days following the second injection. Aqueous and vitreous humor protein concentrations were measured. The presence, number, and type (CD4, 5 and 8) of infiltrating inflammatory cells and amount of tissue destruction were determined. Total RNA was isolated and quantitative reverse transcriptase-polymerase chain reaction was performed for equine specific interleukin (IL) 2 and 4, interferon-gamma (IFN gamma) and beta-actin. In addition, aqueous and vitreous humor and peripheral blood were collected at the termination of the experiments and analyzed for CsA concentration by HPLC. Within 4h of the first intravitreal H37RA-mTB antigen injection, each animal developed epiphora, blepharospasm, mild corneal edema, aqueous flare, myosis, and vitreous opacity. The severity of signs peaked 48 to 72 h after injection and subsequently decreased back to normal within 14 days. Following the second injection, clinical signs in the eyes with the CsA device were less severe and significantly shorter in duration than signs with the polymer only implant eyes. Aqueous and vitreous humor protein levels, infiltrating cell numbers, total number of T-lymphocytes, and levels of IL-2 and IFN gamma-mRNA were significantly less in eyes with the CsA implant compared to eyes with the polymer only. CsA implants did not completely eliminate the development of a second ('recurrent') experimental inflammatory episode in these horses. However, the duration and severity of inflammation, cellular infiltration, tissue destruction, and pro-inflammatory cytokines RNA transcript levels were significantly less in those eyes implanted with the CsA device.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044557     DOI: 10.1016/s0165-2427(00)00219-1

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  6 in total

1.  Biodegradable poly(terephthalate-co-phosphate)s: synthesis, characterization and drug-release properties.

Authors:  Hai-Quan Mao; Irina Shipanova-Kadiyala; Zhong Zhao; Wenbin Dang; Angela Brown; Kam W Leong
Journal:  J Biomater Sci Polym Ed       Date:  2005       Impact factor: 3.517

2.  Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis.

Authors:  Xiaoguang Dong; Weiyun Shi; Gongqiang Yuan; Lixin Xie; Shenguo Wang; Ping Lin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-15       Impact factor: 3.117

Review 3.  A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.

Authors:  Nasiq Hasan; Rohan Chawla; Nawazish Shaikh; Sindhuja Kandasamy; Shorya Vardhan Azad; M Dheepak Sundar
Journal:  Ther Adv Ophthalmol       Date:  2022-05-18

4.  In vivo release and retinal toxicity of cyclosporine-loaded intravitreal device.

Authors:  Felipe Piacentini Paes de Almeida; Juliana Barbosa Saliba; Jefferson Augusto Santana Ribeiro; Rubens Camargo Siqueira; Sílvia L Fialho; Armando Silva-Cunha; Rodrigo Jorge; Andre Messias
Journal:  Doc Ophthalmol       Date:  2015-11-17       Impact factor: 2.379

5.  Immunological and pathological investigations in equine experimental uveitis.

Authors:  Galina P Simeonova; Svetozar Z Krastev; Radostin S Simeonov
Journal:  Vet Res Commun       Date:  2016-06-25       Impact factor: 2.459

6.  Sustained release intraocular drug delivery devices for treatment of uveitis.

Authors:  Nahid Haghjou; Masoud Soheilian; Mohammad Jafar Abdekhodaie
Journal:  J Ophthalmic Vis Res       Date:  2011-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.